Prednisone plus azathioprine vs prednisone
Adverse events · bullous pemphigoid
1 finding from 1 review
- no estimate extractedStudies not reportedVery low
Findings
What do systematic reviews say?
108 questions · 108 findings · 14 reviews · Skin
No studies found 20 · 18.5%GRADE not reported 4 · 3.7%Very low 34 · 31.5%Low 25 · 23.1%Moderate 24 · 22.2%High 1 · 0.9%
Serlopitant 0.25 mg vs placebo
Adverse events · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 0.25 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.29 [0.75, 2.24]1 study · 127 participantsVery low
Serlopitant 5 mg vs placebo
Adverse events · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 5 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.48 [0.87, 2.5]1 study · 127 participantsVery low
Serlopitant 1 mg vs placebo
Adverse events · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 1 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.45 [0.86, 2.47]1 study · 128 participantsVery low
Biotin vs placebo
Adverse events · infantile seborrhoeic dermatitis (including cradle cap)
1 finding from 1 review
- Interventions for infantile seborrhoeic dermatitis (including cradle cap) 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 39 participantsGRADE not reported
Proprietary products vs placebo
Adverse events · infantile seborrhoeic dermatitis (including cradle cap)
1 finding from 1 review
- Interventions for infantile seborrhoeic dermatitis (including cradle cap) 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 166 participantsVery low
Topical steroid vs comparator
Adverse events · infantile seborrhoeic dermatitis (including cradle cap)
1 finding from 1 review
- Interventions for infantile seborrhoeic dermatitis (including cradle cap) 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 105 participantsVery low
Minoxidil 2% vs minoxidil 5%
Adverse events · women with FPHL
Minoxidil 2% showed no clear difference in adverse events compared with minoxidil 5% (low certainty).
1 finding from 1 review
- RR 1.02 [0.91, 1.2]4 studies · 1006 participantsLow
Finasteride vs placebo
Adverse events · women with FPHL
Finasteride showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 1.03 [0.45, 2.34]1 study · 137 participantsLow
Low‐level laser comb vs Placebo (sham/placebo device)
Adverse events · women with FPHL
1 finding from 1 review
- no estimate extracted2 studies · 141 participantsLow
Minoxidil vs placebo
Adverse events · women with FPHL
Minoxidil showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 1.24 [0.82, 1.87]4 studies · 727 participantsLow
Oral hydroxychloroquine vs placebo
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyRR 1.32 [0.24, 7.19]1 study · 47 participantsModerate
Oral dehydroepiandrosterone vs placebo
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone probably leads to higher adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyRR 10.5 [3.26, 33.75]1 study · 381 participantsModerate
Oral chloroquine vs placebo
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Oral methotrexate vs oral chloroquine
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate may leads to higher adverse events: minor compared with oral chloroquine (low certainty).
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyRR 3.9 [1.45, 10.51]1 study · 41 participantsLow
Oral methotrexate vs placebo
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyRR 0.68 [0.39, 1.17]1 study · 86 participantsModerate
Oral hydroxychloroquine vs placebo
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyRR 3.9 [0.19, 78.46]1 study · 71 participantsModerate
Oral dehydroepiandrosterone vs placebo
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyRR 0.09 [0.01, 1.66]1 study · 381 participantsModerate
Oral chloroquine vs placebo
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral chloroquine showed no clear difference in adverse events: severe compared with placebo (low certainty).
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyRR 0.33 [0.01, 7.45]1 study · 24 participantsLow
Oral ciclosporin vs azathioprine (AZA)
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral ciclosporin showed no clear difference in adverse events: severe compared with oral azathioprine (low certainty).
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyRR 0.89 [0.48, 1.65]1 study · 89 participantsLow